ERBB2 and breast cancer: At present, in a prospective study including 34 HER2+ and 16 HER2− BC patients, a standardized uptake value (SUV)max cut-off of 3.2 showed a sensitivity of 76% and a specificity of 62% to distinguish HER2+ from HER2− lesions [11].